S292: SUSTAINED RESPONSE OFF TREATMENT IN ELTROMBOPAG-TREATED PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE STEROIDS: PRIMARY ANALYSIS OF THE PHASE II TAPER TRIAL
N. Cooper,
W. Ghanima,
N. Vianelli,
D. Valcárcel,
I. Yavaşoğlu,
A. Melikyan,
E. Yañez Ruiz,
J. Haenig,
J. Lee,
J. Maier,
N. Zolkin,
F. Zaja
Affiliations
N. Cooper
1 Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, Hammersmith Hospital, London, United Kingdom
W. Ghanima
2 Department of Medicine, Østfold Hospital Trust, Kalnes, Norway
N. Vianelli
3 Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
D. Valcárcel
4 Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), University Hospital Vall d’Hebron, Barcelona, Spain
I. Yavaşoğlu
5 Department of Hematology, Adnan Menderes University, Aydin, Turkey
A. Melikyan
6 National Research Center for Hematology, Moscow, Russia
E. Yañez Ruiz
7 Hematology-Oncology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Temuco, Chile
J. Haenig
8 Novartis Pharma AG, Basel, Switzerland
J. Lee
9 Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States of America
J. Maier
8 Novartis Pharma AG, Basel, Switzerland
N. Zolkin
10 IQVIA, St. Petersburg, Russia
F. Zaja
11 Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
